Switch Therapeutics: Company Market Research Report
Company Overview
Name of the Company
Switch Therapeutics
Mission
Switch Therapeutics is committed to revolutionizing RNA interference (RNAi) by developing biomarker-gated, innovative genetic medicines aimed at transforming the treatment of central nervous system (CNS) diseases.
Founding Details
- Founded: 2020
- Founders: The foundation of Switch Therapeutics was based on RNAi research conducted at Caltech, Harvard Medical School, and City of Hope.
Key People
- Dee Datta, PhD - Co-Founder & CEO
- Charles Allerson, PhD - Chief Technology Officer (CTO)
- Michael Wolfe - Senior Vice President, Finance & Operations
- Craig Blanchette, PhD - Senior Vice President, Research
- Brandi Simpson, MBA - Senior Vice President, Business Development
- Anindya Bhattacharya, PhD - Vice President, Head of Neuroscience
Headquarters
Switch Therapeutics is headquartered in South San Francisco, California.
Number of Employees
No information is available.
Revenue
No information is available.
Recognition
Switch Therapeutics is known for its pioneering CASi (Conditionally Activated siRNA) platform, which is a novel class of RNAi drugs that combine properties of both single and double-stranded RNA into a single molecule for efficient gene knockdown with cell-specific activation.
Products
Overview of Products
Switch Therapeutics develops novel genetic medicines, focusing primarily on their Conditionally Activated siRNA (CASi) platform for treating CNS diseases.
CASi Platform
Description
- CASi molecules incorporate both single and double-stranded RNA into a single molecule, allowing for efficient self-delivery, uptake, and potent durable knockdown. The primary focus is on developing treatments for CNS diseases.
Key Features
- Sensor Domain: Facilitates targeting and activation within specific cell types.
- Payload Domain: Consists of small interfering RNA (siRNA) that is activated in targeted cells.
- Modular Design: Allows future delivery of other RNA payloads potentially.
Pipeline Efforts
Switch Therapeutics is advancing multiple programs targeting neurodegenerative diseases with a focus on:
- APOE: A liver-sparing APOE RNA therapy targeting the ε4 allele, which is a genetic risk factor for Alzheimer's Disease.
- MAPT (Tau): Anti-tau siRNA (CASi-002) to reduce tau protein production, implicated in various tauopathies, including Alzheimer's Disease and frontotemporal dementia.
- C1q: Aiming at microglial C1q inhibition to reduce synaptic pruning in neuroinflammatory contexts without affecting systemic immunity.
Recent Developments
New Developments
- Switch Therapeutics announced its first development candidate CASi-APOE, a liver-sparing APOE RNAi therapy, to address Alzheimer's disease-related APOE*ε4 allele risks.
- Switch Therapeutics moved into its new facility in South San Francisco post-early 2022 after raising $52 million in financing.
New Appointments and Partnerships
- David M. Holtzman, M.D. was appointed to the Scientific Advisory Board to support the advancement of their neurodegenerative pipeline.
- Charles Allerson, Ph.D. was appointed as CTO to lead the company’s CASi platform initiatives.
Conferences
- Scheduled presentations at key industry conferences, including H.C. Wainwright Neuro Perspectives Virtual Conference, Evercore ISI 2024 Emerging Biotech Conference, and Morgan Stanley 21st Annual Global Healthcare Conference.
Partnerships
Switch Therapeutics has received additional funding from prominent investors, including Eli Lilly and Company.
Conclusion
Switch Therapeutics is strategically positioned as a leading innovator within the RNAi sector focused on CNS indications. Through its CASi platform, the company endeavors to address unmet medical needs with precision RNAi therapies, heralding a new frontier in combating devastating neural pathologies.
